Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has deployed $35 million so far toward the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females.
Juneau hopes to launch an FDA approved kit (sold through partners with established franchises in women’s health) for evaluation of symptomatic women. Over 25 million women in the United States are being evaluated or treated for chronic pelvic pain at any time, and endometriosis is often the underlying cause of their pain. Additional revenues will come from out-licensing novel drug targets for preventing and treating endometriosis.
Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women.
For information regarding investment or partnership opportunities, please contact: